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Objectives. We sought to describe the various cardiovascular 
complications that occurred in the Lyon Diet Heart Study (a 
secondary prevention trial testing the protective ffects of a 
Mediterranean type of diet), to analyze their relations with the 
associated rug treatments and to gain insights into the possible 
mechanisms underlying the beneficial effects of certain nutriments. 
Background. Dietary habits are implicated in coronary heart 
disease, and the traditional Mediterranean diet is thought o be 
cardioprotective. However, the exact mechanisms of this protec- 
tion are unknown. 
Methods. A total of 605 patients (303 control subjects and 302 
study patients) were studied over a mean period of 27 months. 
Major primary end points (cardiovascular death and nonfatal 
acute myocardial infarction), secondary end points (including 
unstable angina, stroke, heart failure and embolisms) and minor 
end points (stable angina, need for myocardial revascularization, 
postangioplasty restenosis and thrombophlebitis) were analyzed 
separately and in combination. 
Results. When major primary and secondary end points were 
combined, there were 59 events in control subjects and 14 events 
in the study patients, showing a risk reduction of 76% (p < 
0.00011. When these end points were combined with the minor end 
points, there were 104 events in control subjects and 68 events in 
the study patients, giving a risk reduction of 37% (p < 0.005). By 
observational nalysis, only aspirin among the medications ap- 
peared to be significantly protective (risk ratio after adjustment 
for prognosis factors 0.45; 95% confidence interval 0.25 to 0.80). 
Conclusions. These data show a protective ffect of the Medi- 
terranean diet. However, the risk reduction varied depending on 
the type of end point considered. Our hypothesis that different 
pathogenetic mechanisms were responsible for the development of 
the various complications. It is likely that certain nutriments 
characteristic of the Mediterranean diet (omega-3 fatty acids, 
oleic acid, antioxidant vitamins) have specific cardioprotective 
effects. 
(J Am Coil Cardiol 1996;28:1103-8) 
Although dietary habits were thought to be implicated in 
coronary heart disease and previous dietary trials showed 
inconsistent results (1), few controlled dietary trials were 
initiated during the last decade, probably because of the many 
technical difficulties inherent in such studies. However, previ- 
ous simplistic hypotheses were finally abandoned and the need 
for multifactorial intervention was recognized 0-3).  In partic- 
ular, the concept of the traditional ethnic cardioprotective diet 
recently emerged (1-5). 
The Lyon Diet Heart Study, whose primary results have 
been published (3), is a secondary prevention trial that dem- 
onstrated a protective ffect of a Mediterranean type of diet in 
survivors of a first recent myocardial infarction. Because a 
chance effect could not be totally eliminated although recent 
dietary trials in Great Britain (2) and India (4), based on 
similar approaches, howed results comparable to those of the 
Lyon study, complementary data regarding secondary and 
minor end points may help to evaluate plausibility of the 
results. The aims of the present study were therefore to report 
the various cardiovascular events that occurred in the control 
and study groups during the Lyon trial, to analyze their 
relation with the associated rug treatment and to gain insights 
into the possible mechanism or mechanisms underlying the 
beneficial effects of the Mediterranean type of diet tested in 
the trial. 
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Methods  
Study design and participants. The study design, partici- 
pants and most of the methods of the Lyon Diet Heart Study 
have becn described (3). Briefly, the study is a randomized 
single-blind trial to test the hypothesis that a Mediterranean 
type of diet may reduce the risk of cardiovascular complica- 
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Abbreviations and Acronyms 
ACE = angiotensin-converting e zyme 
CI = confidence interval 
ECG = electrocardiogram 
tions in survivors of a first acute myocardial infarction. A 
two-step recruitment technique, a modification of the Zelen 
design (6), was used. Patients who agreed to be followed up for 
5 years by the Research Unit (annual visit including clinical 
examination by a cardiologist, electrocardiogram (ECG) and 
blood sampling for routine biologic measurements) signed a 
first consent form and were randomly assigned to a control or 
a study group. At this stage, patients of both groups were not 
fully informed about he study and only patients randomized to 
the study group were invited to sign a second consent form in 
which they agreed to adopt a Mediterranean type of diet. This 
design was used 1) to avoid between-group contamination, a 
major difficulty in dietary trials; and 2) to avoid influencing 
how physicians would follow up and treat their patients in the 
event of new symptoms or a heart attack. It was indeed 
suspected that knowledge of group assignment by physicians in 
both groups could cause them, consciously or not, to modify 
their usual practice and consequently influence results of the 
trial. Thus, control subjects did not receive dietary information 
from the investigators of the study. They were expected to 
follow the dietary advice given by their attending physicians, 
similar to that of step 1 of the prudent diet of the American 
Heart Association. 
After the randomization visit, patients of both groups were 
scheduled to be seen 2 months later and then annually at the 
Research Unit. These visits did not replace their regular visits 
to the attending physicians, who were responsible for all 
aspects of treatment, including use of medication and of in- 
vasive diagnostic and therapeutic procedures. 
The main characteristics of the Mediterranean type of diet 
tested in the study group have been previously reported (3,5). 
Briefly, this diet was designed to supply 1) <35% of energy as 
fat; 2) <10% of energy as saturated fat; 3) <4% of energy as 
linoleic acid [18:2 (n-6)]; 4) >0.6% of energy as alpha-linolenic 
acid [18:3 (n-3)]. In practical terms, the dietary instructions 
were personalized and described in detail to each patient. The 
techniques used to obtain changes derived from those recom- 
mended in other contexts by Erickson and Rossi (7) and 
Watzlawick (8). Briefly, patients were advised to modify their 
regular diet in two stages. The aim of stage 1 was to prepare 
patients to accept he detailed instructions given in the second 
stage. Stage 2 of the intervention was conducted by the 
dietitian of the study and consisted of helping patients and 
their family to adapt heir usual diet to the Mediterranean type 
of diet tested in the trial. At this stage the dietitian needed to 
take into account such factors as the wishes and gastronomic 
preferences of the patients, the geographic origin of the family 
(e.g., south or north of France, Spain, Italy, North Africa), the 
job of the patient, the number of persons at home, financial 
resources and community where the family lives (e.g., center of 
city, small village). Instructions had to be detailed, easy to 
execute, safe, not expensive and compatible with the way of 
living (e.g., unmarried, couple, large family, retired), race, 
gender and religion of each patient. 
Primary and secondary end points. Whereas cardiovascu- 
lar death and nonfatal acute myocardial infarction were the 
primary end points of the trial, secondary end points were also 
scrupulously documented and recorded provided they required 
hospital admission. These end points included 1) episodes of 
unstable angina (defined as spontaneous rest angina, decubitus 
and nocturnal angina or exercise angina that recently increased 
in frequency or duration or that was increasingly resistant to 
antianginal therapy); 2) recurrent stable angina whose severity 
necessitated in-hospital invasive investigations; 3) episodes of 
overt heart failure (New York Heart Association functional 
class III or IV); 4) transient or permanent cerebral stroke; 5) 
pulmonary embolism; 6) peripheral arterial embolism; 7) 
thrombophlebitis; 8) need for myocardial revascularization 
(angioplasty or bypass surgery, or both); 9) postangioplasty 
restenosis (diagnosis based on the association of recurrent 
angina and confirming angiography). 
Among patients admitted to the hospital with the diagnosis 
of unstable or stable angina, only those who underwent 
coronary angiography to document severity and aspects of 
coronary lesions were included in the analysis. The need for 
myocardial revascularization (bypass urgery or percutaneous 
coronary angioplasty) and periproeedural complications (myo- 
cardial infarction and clinically significant coronary artery 
restenosis after angioplasty) were also considered secondary 
end points. 
Detailed information on each end point was collected from 
hospital records, and raw data were reviewed in blinded 
manner, validated and classified according to predefined cri- 
teria by the two experienced cardiologist members of the 
Endpoint Committee (3). 
Statistical analysis. Analyses were performed according to 
the intention-to-treat principle and with the use of two-sided 
tests. In life-table analyses and the Cox model, the time of the 
first event (either major primary, secondary or minor end 
point) was used. The log-rank test was used to compare 
survival curves, and adjusted risk ratios were calculated by the 
Cox proportional hazards model. In analyses of combined end 
points, end points were mutually exclusive. We also examined 
the protective role of the anti-ischemic or major cardiac drugs, 
including anticoagulant agents, aspirin, beta-adrenergic block- 
ing agents, calcium-channel blocking agents and inhibitors of 
the angiotensin-converting e zyme (ACE). 
To analyze the relation between drug treatment and the 
occurrence of new complications, we included in the calcula- 
tions only the major complications: the combination of cardiac 
death and nonfatal infarction and this combination plus cere- 
bral stroke, unstable angina, heart failure, pulmonary and 
peripheral embolism. 
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Table 1. Use of Anti-Ischemic and Major Cardiac Drugs 
Study Group Control Group 
Baseline 1st Year Baseline 1st Year 
Oral anticoagulant agents 29.4% 21.8% 26.4% 18,7% 
Aspirin 64.8% 65.3% 62.6% 60.9% 
Beta-blocking agents 60.2% 47.6%* 63.4% 47.4%* 
Calcium channel blockers 20.4% 25.8~ 21.7% 29.5% 
ACE inhibitors 9.3% 15.2% 6.1% 9.2% 
*p < 0.05 versus baseline. Similar figures were observed uring follow-up 
beyond the 1st year. Data presented are percent of patients in group. ACE = 
angiotensin-converting e zyme. 
Resu l ts  
The main data of the Lyon Diet Heart Study regarding 
patient accrual, baseline characteristics, follow-up and rate of 
withdrawal have been reported (3). Although recruitment was 
started in March 1988, an intermediate analysis was proposed 
by the Scientific Committee after a follow-up period of -> 1 year 
for each patient. This analysis was performed in March 1993 
(3). 
A total of 605 patients (303 control subjects and 302 study 
patients) were randomized and included into the analysis. 
Patients were primarily male, with a male/female ratio of 
-90/10 in both groups. The mean age ± SD was 53.5 _+ 10 
years in both groups. Other baseline characteristics except for 
smoking were similar in both groups. The proportion of 
smokers at randomization was higher in the study group 
(7.6%) than in the control group (4.9%, p < 0.05); after 1 year, 
the difference (19% vs. 15%) was not significant and continued 
to be insignificant in subsequent years. 
The use of anti-ischemic agents and ACE inhibitors did not 
differ between groups at randomization or during follow-up 
(Table 1). Aspirin use was stable during follow-up, indicating 
that the drug is well tolerated at low dosage (-250 mg/day) in 
such patients, whereas the use of anticoagulant agents de- 
creased slightly after 1 year, a reduction that is concordant with 
the current practice of French physicians. Between random- 
ization and the 1-year visit, there was a small but significant 
(p < 0.05) reduction i  the use of beta-blocking agents in both 
groups that suggests either that these agents were not well 
tolerated or that physicians were not persuaded of their 
usefulness beyond the 1st year after infarction. For calcium 
channel blockers and ACE inhibitors, there was a nonsignifi- 
cant tendency to increased use after 1 year, probably to 
compensate for the reduced use of beta-blockers. 
Taken together, the data regarding medication use show a 
parallel course in the two groups over the years, which suggests 
that the participation of patients in the trial did not influence 
the current practice of the attending physicians in either group. 
This is a major point to be considered when discussing the 
question of physician bias in a single-blind trial such as the 
Lyon study (see later discussion). 
Primary and secondary end points. Results for the primary 
end point (combination of cardiovascular death and nonfatal 
Table 2. Primary and Major and Minor Secondary End Points in 
the Two Groups 
Control Group Study Group 
(n = 3/)3) (n = 302) 
Events Events 
(no.) Rate* (no.) Rate* 
Major primary, end points 
CV deaths 16 2.69 3 0.50 
Nonfatal myocardial infarction 17 2.86 5 0.82 
Subtotal 33 5.55 8 1.32 
Non-CV deaths 4 0.67 5 0.82 
Overall mortali~' 20 3.37 8 1.32 
Major secondary end points 
Periprocedural infarction 2 0 
Unstable angina 21 3.53 4 0.66 
Nonfatal heart failure 8 1.35 2 0.33 
Stroke 3 0 
Pulmonary embolism 2 0 
Peripheral embolism 1 0 
Subtotal 37 6.23 6 0.99 
Minor secondary end points 
Stable angina 27 4.54 17 2.81 
Elective myocardial revascularization 4l 6.90 31 5.11 
(angioplasty/bypass surgery) 
Postangioplasty restenosis 15 2.53 9 1.49 
Thrombophlcbitis 1 1 
Subtotal 84 14.14 58 9.57 
*Per 10{) patients per year of follow-up. CV - cardiovascular. 
acute myocardial infarction) have been reported (3). These 
data are summarized in Table 2, which also summarizes data 
on major and minor secondary end points. The results are 
based on a total of 594 person-years in the control group and 
606 person-years in the study group. 
To be noted is the large difference between groups in the 
number of new infarctions and episodes of unstable angina. 
When primary and major secondary end points were combined 
in the proportional hazards model, there were 59 events in the 
control group and 14 in the study group. The risk ratio was 0.24 
(95% confidence interval [CI] 0.13 to 0.44, p < 0.0001) after 
adjustment for age, gender, smoking status, serum cholesterol, 
systolic blood pressure and infarct location. Survival curves are 
shown in Figure 1. 
When the preceding major primary and secondary end 
points were combined with the minor end points in the same 
way as before, there were 104 events in the control group and 
68 in the study group, giving a risk ratio of 0.63 (95% CI 0.46 
to 0.87, p < 0.005). Survival curves are shown in Figure 2. 
Relations between medication use and the various end 
points. Regarding combined cardiac death and nonfatal acute 
myocardial infarction (n = 41), the use of aspirin was the sole 
factor significantly (and inversely) associated with new events 
(Table 3A). When secondary end points were added to the 
analysis (n = 73, Table 3B), aspirin use remained significantly 
and inversely associated with new events. The use of anticoag- 
ulant agents and ACE inhibitors became of borderline signif- 
icance. 
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Figure 1. Survival curves for combined cardiac death, nonfatal infarc- 
tion, unstable angina, heart failure, stroke and thromboembolism. 
Log-rank test using the time of the first event was used to compare the 
control and study (EXPERIMENTAL) groups. There was already a
striking difference between the two groups within the 1st year (p < 
0.0001). 
Discussion 
Summary of results. These data extend the finding that the 
Mediterranean type of diet tested in the trial was protective in
survivors of a first infarction. The absolute number of events is 
a critical point to be considered when examining the results of 
any trial. Whereas the combination of cardiovascular death 
and nonfatal infarction was the primary end point used in the 
statistical calculations to define sample size and duration of 
follow-up, secondary, and minor end points (provided they 
were validated and classified by an independent committee) 
were also considered. Thirty-seven major secondary events, 
including cerebral stroke, major episodes of cardiac decom- 
pensation, episodes of unstable angina and various types of 
embolism, occurred in the control group in contrast to six in 
the study group. The ratio was 33:8 for the primary end points, 
cardiac death and nonfatal infarction (3). This finding shows 
that the data on primary and secondary end points are 
concordant, and it adds plausibility to the overall message of 
the trial. However, when major primary and secondary events 
Figure 2. Survival curves for combined major primary and secondary 
end points and minor end points including episodes of stable angina 
necessitating hospital admission, eed for elective myocardial revas- 
cularization, postangioplasty restenosis and venous thrombophlebitis. 
Although statistically significant (p = 0.0018), the difference between 
groups hown here was less impressive than that shown (Fig. 1) when 
fewer events were included in the analysis (see text for details). 
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Table 3. Relation Between the Use of Anti-Ischemic and Cardiac 
Drugs and thc Occurrence ofNew Cardiac Events 
Risk Ratio 
(95% CI)* 
A. Cardiac Death and Nonfatal AMI 
Anticoagulant agents 
Aspirin 
Beta-blocking agents 
Calcium channel blocker 
ACE inhibitors 
0.50 (0.22-1.19) 
0.46 (0.22-0.99) 
1.05 (0.50-2.22) 
1.82 (0.83-4.02) 
2.63 (0.86-8.04) 
B. Cardiac Death, Nonfatal AMI  and Other Events] 
Anticoagulant agents 0.51 (0.27-0.98) 
Aspirin 0.45 (0.25-0.80) 
Beta-blocking agents 1.26 (0.72-2.20) 
Calcium-channel blocker 1.31 (0.70-2.44) 
ACE inhibitors 2.57 (1.17-5.68) 
*Risk ratios are given after adjustment for age, gender, diet group assign- 
ment, systolic blood pressure, total cholesterol and infarct location (anterior vs. 
other), tOther events are the major secondary end points described in the 
Methods ection and in Table 2. ACE angiotensin-converting enzyme; AMI = 
acute myocardial infarction. 
were combined with the minor events, the difference between 
groups was much less impressive. The reduction of risk was 
37% in contrast to 76% when only primary and secondary end 
points were included. This finding suggests that when more 
events (104 in the control group vs. 68 in the study group) are 
included, the difference between groups is attenuated and 
perhaps more realistic. Another hypothesis that the patho- 
genetic mechanisms underlying the various events are different 
and were differently influenced by the nutriments characteristic 
of the Mediterranean diet. 
The greatest differences between groups occurred with 
nonfatal infarction (17 events vs. 5) and unstable angina (21 
events vs. 4). This is not surprising because the two complica- 
tions are related to similar pathogenetic mechanisms (9-11). 
In both myocardial infarction and unstable angina, localized 
arterial inflammation, plaque ulceration and acute occlusive or 
subocclusive thrombosis are thought o be causal mechanisms 
(9-11). In contrast, recurrent stable angina probably results 
from the slow progression of the arterial disease, which is 
probably related to a different mechanism. In addition, the 
occurrence of certain minor end points such as the need for 
coronary angiography or revascularization (bypass urgery or 
angioplasty) depends, at least in part, on the official policy in a 
given cardiology center or on the beliefs of physicians rather 
than on objective clinical status alone. Thus, in the present 
trial, we cannot exclude the possibility of a physician bias; that 
is, that the physicians of the control group might have managed 
their subjects more aggressively (using invasive diagnostic and 
therapeutic procedures more often) than did the physicians of 
the study patients. However, this possibility is quite unlikely 
because no difference between the two groups in the use of 
medication was detectable. Indeed, more intensive drug treat- 
ment in the control patients would have been detected if their 
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physicians had actually intended, consciously or not, to com- 
pensate for the difference in diet group assignment by more 
frequently prescribing anti-ischemic drugs as well as coronary 
angiography, bypass urgery and angioplasty. 
Among the medications used by the patients in the Lyon 
study, aspirin was significantly and inversely associated with the 
occurrence of new events. The positive association between 
ACE inhibitors and the occurrence of new events can probably 
be explained by the fact that at the time of the study, ACE 
inhibitors were usually prescribed to patients with a very poor 
prognosis, with a large anterior infarction or a prior episode of 
heart failure, or both. Thus, the use of ACE inhibitors in that 
context should be considered a marker of a major alteration of 
left ventricular function at the time of randomization rather 
than a factor implicated in the occurrence of new events. 
Which nutriments of the Mediterranean diet were cardio- 
protective? To evaluate the plausibility of the results of the 
trial, it is important o try to identify which biologic factors 
modified by the Mediterranean diet may have been cardiopro- 
tective. Two major biologic factors were modified by the 
intervention: 1) the antioxidant vitamins, alpha-tocopherol and 
ascorbic acid, which were increased in the plasma of the study 
patients (3,5); 2) the plasma fatty acid profile, with a noticeable 
increase in omega-3 fatty acids and a decrease in omega-6 fatty 
acids in the study group (3,5). Other factors such as the 
antioxidant flavonoids (12) and minerals, arginine, glutamine 
and methionine (13-15) and vitamins of the B group including 
folic acid (16,17) probably played important roles but were not 
measured in the study. 
Favorable ffects of omega-3 fatty acids were reported in 
association with elevation of their plasma levels (18), for 
instance, antiarrhythmogenic effect (19-21). A low fat diet 
enriched in monounsaturated fatty acids (22,23) is also char- 
acteristic of the Mediterranean diet, and its favorable ffects 
have been extensively discussed (24). 
In fact, several ines of evidence indicate that the major 
mechanisms leading to acute arterial manifestations--in par- 
ticular, sudden death, unstable angina and myocardial infarc- 
tion-in various conditions including heart transplantation 
(25-28) are localized inflammation and immune-mediated 
processes with macrophage infiltration (29) preceded or fol- 
lowed, or both, by lipid modification (oxidation) and accumu- 
lation. These initiating events eventually lead to lesion hem- 
orrhage, plaque ulceration and rupture and, ultimately, 
occlusive or subocclusive coronary thrombosis (10,11). Some 
of these processes were apparently prevented in the study 
patients of the Lyon trial. 
The next question therefore should be whether certain 
nutriments of the Mediterranean diet are able to prevent or 
reduce plaque inflammation. Recent studies in humans (30,31) 
have shown a direct influence of dietary fatty acids on the fatty 
acid composition of arterial esions. Rapp et al. (30) reported 
the incorporation of dietary omega-3 fatty acids in obstructive 
arterial lesions within some days after starting supplementa- 
tion. The striking feature of their study conducted in humans 
was the rapidity with which the atherosclerotic lesions were 
loaded with omega-3 fatty acids. The arterial esions at risk of 
rupture are known to be lipid-rich, young and not very fibrotic 
or very stenotic (25-27). Incorporation of new fatty acids at a 
rapid rate by means of dietary changes in young and dangerous 
lesions is thus conceivable in patients who have consumed an 
alpha-linolenic-rich diet. This possibility may explain why in 
recent dietary trials, beneficial effects in dieters were apparent 
within a few weeks after start of the trial (2-4). Omega-3 fatty 
acids may have an anti-inflammatory and stabilizing effect on 
the lipid-rich lesions because they have been shown in various 
animal models (32,33) and in humans (34-37) to interfere with 
the many secretory and proinflammatory properties of leuko- 
cytes. They prevent he development of atherosclerotic lesions 
in rabbits and mice by modulating macrophage secretory 
activities (32,33), whereas the activated lesion macrophages 
seem to be the main determinants ofplaque inflammation and 
rupture in humans (26,29). Thus, loading plaque with omega-3 
fatty acids, as occurs in patients with high intake and high 
plasma levels of omega-3 fatty acids (30,31), can induce local 
anti-inflammatory activity. 
Oxidized lipids are also thought to play a major role in 
arterial complications by stimulating macrophages, injuring 
endothelial cells and promoting leukocyte coagulant activity 
and platelet reactivity (38). The nature of the substrate for 
lipid peroxidation, mainly the polyunsaturated fatty acids, is a 
dominant influence in determining the rate of peroxidation, in
association with the content of antioxidants (38). The impor- 
tance of the fatty acid composition of lipids in determining 
their susceptibility ooxidation was impressively demonstrated 
by recent studies (39,40) comparing lipoproteins enriched in 
either linoleate or oleate in both animal models and humans: 
Lipids enriched in oleate were remarkably resistant to oxida- 
tion. The study group in the Lyon study had a plasma fatty acid 
profile extremely favorable for protecting circulating or tissue 
lipids against oxidation; oleic acid intake was increased, lino- 
leic acid intake was decreased (3,5) and similar profiles were 
observed in plasma (3,5). Also, antioxidant defenses were 
reinforced with higher plasma levels of antioxidant vitamins 
(3,5). This effect probably protected against uncontrolled lipid 
oxidation (38), suppressed leukocyte production of reactive 
oxygen species (41) and inhibited monocyte function (42). In 
addition, the ratio of arachidonic acid to eicosopentanoic a id 
in the plasma (see Ref 3) was also extremely favorable for 
obtaining an antithrombotic effect through an improved bal- 
ance in the generation of prostacyclin and thromboxane 
(43,44). This is a major point because lesion ulceration and 
plaque disruption eventually culminate in thrombotic occlu- 
sion, which is thought o determine the acuteness ofthe clinical 
presentation (11). 
We conclude that the present data support he view that 
comprehensive dietary modifications can rapidly induce a 
multitude of significant biologic changes at various cellular and 
molecular levels. These changes are probably capable of 
interfering with the pathogenesis of acute coronary events. 
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